CTOs on the Move

Howard Center

www.howardcenter.org

 
Situated alongside Lake Champlain, we are the largest private non-profit human services organization in the State of Vermont. Since 1865, Howard Center has been helping people and communities thrive by providing supports and services to address mental health, substance use, and developmental needs. Today, we employ 1,600 staff providing services in 60 locations serving more than 16,000 community members annually. Through our competitive and award-winning benefits, work-life balance and equal opportunity employment, we build teams of dedicated, passionate individuals who embrace our mission and are committed to making a lasting contribution to the lives of the people we serve. The ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Memometal

Memometal is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brooklyn Manor Home for Adults

Brooklyn Manor Home for Adults is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blackline Marketing

Blackline Marketing specializes in helping clients in the hospitality, travel, restaurant, health care, business services, retail and food/beverage industries create integrated marketing solutions that increase revenues and maximize long-term customer engagement. Blackline Marketing helps clients in the areas of brand strategy, customer strategy, integrated marketing planning and people/process development. Clients include Northcott Hospitality/Houlihan`s restaurants, Caribou Coffee Company, HealthSource Solutions, ARC/Value Village Stores, Pebble Creek Golf Club and the MN Women`s Public Golf Association.

AirLife

AirLife is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.